Spots Global Cancer Trial Database for malignancies
Every month we try and update this database with for malignancies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | NCT02808780 | Ulcerative Coli... | 18 Years - | Janssen Biotech, Inc. | ||
| Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies | NCT03838926 | Relapsed or Ref... | Trichostatin A | 18 Years - | Vanda Pharmaceuticals | |
| Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies | NCT05602103 | Malignancies Cardiovascular ... Children, Only | use of anticanc... | 0 Years - 18 Years | University Hospital, Caen | |
| Post-Marketing Surveillance Study of OTEZLA | NCT03284879 | Psoriasis | - | Amgen | ||
| A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors. | NCT00676910 | Neoplasms | JNJ-26854165 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Clinical Study of WT2725 in Patients With Advanced Malignancies | NCT01621542 | Cancer | WT2725 | 18 Years - | Sumitomo Pharma America, Inc. | |
| Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies | NCT00496860 | Progressive Met... | ALT-801 | 18 Years - | Altor BioScience | |
| The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. | NCT03384511 | Malignancies Stomach Cancer Non-small Cell ... Esophageal Canc... Breast Cancer Ovary Cancer Cervical Cancer | Apatinib | 18 Years - | Shandong Cancer Hospital and Institute | |
| Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies | NCT00329329 | Malignancies | satraplatin and... | 18 Years - | Agennix | |
| A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies | NCT05253105 | Previously Trea... Malignancies | TAB006 Toripalimab | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies | NCT00741403 | Advanced Cancer Metastatic Canc... Lymphoma Solid Tumors Advanced Malign... | CPI-613 | 18 Years - | Cornerstone Pharmaceuticals | |
| Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies | NCT03838926 | Relapsed or Ref... | Trichostatin A | 18 Years - | Vanda Pharmaceuticals | |
| Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies | NCT00246103 | Neoplasms, Adva... | Valproic acid Epirubicin 5-fluorouracil Cyclophosphamid... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of PWT33597 Mesylate in Subjects With Advanced Malignancies | NCT01407380 | Malignancies | PWT33597 mesyla... | 18 Years - | Pathway Therapeutics, Inc. | |
| Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | NCT03005782 | Malignancies | REGN3767 cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Intraosseous Infusion of Unrelated Cord Blood Grafts | NCT00967525 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... | cord blood infu... | 36 Months - 60 Years | Emory University | |
| Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 | NCT02521389 | Malignancies | PWT-143 | 18 Years - 65 Years | MEI Pharma, Inc. | |
| Study of PWT33597 Mesylate in Subjects With Advanced Malignancies | NCT01407380 | Malignancies | PWT33597 mesyla... | 18 Years - | Pathway Therapeutics, Inc. | |
| Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies | NCT00329329 | Malignancies | satraplatin and... | 18 Years - | Agennix | |
| Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma | NCT00316511 | Malignancies B-Cell Lymphoma | Aroplatin | 18 Years - | Agenus Inc. | |
| Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy | NCT01404728 | Malignancies Stenosis of Vag... | 18 Years - | University of Colorado, Denver | ||
| Intraosseous Infusion of Unrelated Cord Blood Grafts | NCT00967525 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... | cord blood infu... | 36 Months - 60 Years | Emory University | |
| Post-Marketing Surveillance Study of OTEZLA | NCT03284879 | Psoriasis | - | Amgen | ||
| Omics of Cancer: OncoGenomics | NCT05431439 | Neoplasms Cancer | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies | NCT05253105 | Previously Trea... Malignancies | TAB006 Toripalimab | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 | NCT02521389 | Malignancies | PWT-143 | 18 Years - 65 Years | MEI Pharma, Inc. | |
| 9-ING-41 in Patients With Advanced Cancers | NCT03678883 | Cancer Pancreatic Canc... Sarcoma Renal Cancer Refractory Canc... Refractory Neop... Refractory Non-... Pancreatic Aden... Resistant Cance... Neoplasm Metast... Neoplasm of Bon... Neoplasm, Breas... Neoplasm of Lun... Neoplasms,Color... Neoplasms Pancr... Malignant Gliom... Malignancies Malignancies Mu... Bone Metastases Bone Neoplasm Bone Cancer Pancreas Cancer Pancreatic Neop... Breast Neoplasm... Acute T Cell Le... | 9-ING-41 Gemcitabine - 2... Doxorubicin. Lomustine Carboplatin. Nab paclitaxel. Paclitaxel. Gemcitabine - 2... Irinotecan | 18 Years - | Actuate Therapeutics Inc. | |
| A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register | NCT05413044 | Rheumatoid Arth... Psoriatic Arthr... | 18 Years - | Bristol-Myers Squibb | ||
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | NCT03236857 | Malignancies Acute Lymphobla... Acute Myeloid L... Non-Hodgkin's L... Neuroblastoma | chemotherapy venetoclax | 0 Years - 25 Years | AbbVie | |
| Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors | NCT02257476 | Neoplasms Malignancies | Carfilzomib Dexamethasone | 18 Years - | Emory University | |
| Study of E7046 in Subjects With Selected Advanced Malignancies | NCT02540291 | Tumors | E7046 | 18 Years - 99 Years | Eisai Inc. | |
| Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies | NCT05602103 | Malignancies Cardiovascular ... Children, Only | use of anticanc... | 0 Years - 18 Years | University Hospital, Caen | |
| Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) | NCT00112372 | Cancer | Ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies | NCT02961101 | Malignancies Mu... | Anti-PD-1 antib... Decitabine Chemotherapy | 12 Years - 75 Years | Chinese PLA General Hospital | |
| A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies | NCT00741403 | Advanced Cancer Metastatic Canc... Lymphoma Solid Tumors Advanced Malign... | CPI-613 | 18 Years - | Cornerstone Pharmaceuticals | |
| Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies | NCT02961101 | Malignancies Mu... | Anti-PD-1 antib... Decitabine Chemotherapy | 12 Years - 75 Years | Chinese PLA General Hospital | |
| A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies | NCT00441337 | Carcinoma, Non-... Colorectal Canc... Malignant Melan... Renal Cancer Prostate Cancer | MDX-1106 | 18 Years - | Bristol-Myers Squibb | |
| An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | NCT02808780 | Ulcerative Coli... | 18 Years - | Janssen Biotech, Inc. | ||
| Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies | NCT02961101 | Malignancies Mu... | Anti-PD-1 antib... Decitabine Chemotherapy | 12 Years - 75 Years | Chinese PLA General Hospital | |
| Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) | NCT00320827 | Malignancies Lymphoma | CS-1008 (humani... | 18 Years - | Daiichi Sankyo | |
| A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database | NCT05421442 | Rheumatoid Arth... Psoriatic Arthr... | 18 Years - | Bristol-Myers Squibb | ||
| Omics of Cancer: OncoGenomics | NCT05431439 | Neoplasms Cancer | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| Clinical Study of WT2725 in Patients With Advanced Malignancies | NCT01621542 | Cancer | WT2725 | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register | NCT05413044 | Rheumatoid Arth... Psoriatic Arthr... | 18 Years - | Bristol-Myers Squibb | ||
| Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS | NCT05350748 | Myelodysplastic... | 1 Day - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma | NCT00316511 | Malignancies B-Cell Lymphoma | Aroplatin | 18 Years - | Agenus Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
